62 results about "Chikungunya" patented technology

The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.

The invention relates to a preparation method of virus-like particles (VLPs) of Chikungunya virus (CHIKV). The method comprises the steps of: modifying genetic elements of a structural protein encoding gene C-E3-E2-6K-E1 of CHIKV, cloning the modified genetic elements into the expression vector of an insect cell, then transfecting the obtained recombined expression vector and baculovirus linear DNA respectively to an SF9 insect cell and making the cell secrete and express CHIKV VLPs. Additionally, the invention also makes preliminary studies on the immune effects of CHIKV VLPs and applicationof CHIKV VLPs in virus specific antibody detection, thus laying a foundation for research and preparation of immunological detection reagents and even vaccines based on CHIKV VLPs.

Consensus CHIKV E1 protein, consensus CHIKV E2 protein, consensus CHIKV capsid protein, or fragments and homologues thereof, and nucleic acid molecules that encode the same are disclosed. A consensus CHIKV Env protein which includes CHIKV E1 consensus protein, CHIKV E2 consensus protein, CHIKV E3 consensus protein, or fragments and homologues thereof and nucleic acid molecules that encode the same are also disclosed. Compositions and recombinant vaccines comprising CHIKV consensus proteins, and methods of using them are disclosed.

Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.

The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.

The invention discloses a triple detection method of arbovirus liquid chips. The method comprises the following steps: respectively designing specific primers and probes aiming at three types of arboviruses comprising Chikungunya viruses, Crimean-Congo hemorrhagic fever and Rift Valley fever viruses, determining the specificity of the primers and the probes via a single PCR and clone sequencing, and then carrying out multiplex-PCR amplification under the condition that the concentration ratio of the forward and reverse primers in an amplification reaction system is 1:1-1:8; then coupling the probes with fluorescent coding microspheres so as to prepare a microsphere mixing liquid and carrying out coupling quality control by coupling the probes; finally, carrying out a hybridization reaction on multiplex-PCR products and the microsphere mixing liquid, simultaneously adding streptomycin-phycoerythrin diluted by a nucleic acid detection buffer solution, and analyzing reaction products by utilizing a liquid chip detecting instrument. The method is good in detection specificity and can be used for simultaneously detecting the three types of arboviruses, and has high detection sensitivity due to the adoption of an asymmetric PCR amplification method in the process of the multiplex-PCR amplification.

Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.

The present invention discloses a DNA molecule having a nucleotide sequence represented by SEQ ID NO:1, and uses thereof, and further discloses a Chikungunya virus DRDE-06 strain labeling method, recombinant plasmid containing the DNA molecule, a construction method of the recombinant plasmid, infectious clone of the Chikungunya virus having the genomic RNA corresponding cDNA nucleotide sequence represented by SEQ ID NO:1, and a construction method of the infectious clone. According to the present invention, the DNA molecule or the recombinant plasmid can be used for constructing the Chikungunya virus infectious clone having the performance similar to the wild-type virus.

The invention relates to the technical field of biological medicines, and provides an amino acid sequence of a chikungunya virus (CHIKV) E2 protein rabbit monoclonal antibody and application thereof. The amino acid sequence of the CHIKV E2 protein rabbit monoclonal antibody comprises an amino acid sequence of a heavy chain and an amino acid sequence of a light chain of the antibody. The antibody expressed by mammalian cells can neutralize infection of CHIKV genotypes which are mainly popular in the world on the cells in vitro, and can protect type I interferon receptor genes from knocking out mice to resist fatal CHIKV infection in vivo. The antibody is modified, such as humanized modification or preparation of a single-chain antibody, and is expected to be used for treating severe CHIKV infection.

The invention discloses a Chikungunya virus specific detection antigen and an application thereof. The Chikungunya virus specific detection antigen provided by the invention is a polypeptide shown as any of (a1), (a2) and (a3), wherein (a1) is a polypeptide shown as a sequence 1 or a 166-378 site of the sequence 1; (a2)is a polypeptide shown as a sequence 2 or a 166-392 site of the sequence 2; and (a3) is a polypeptide which is obtained by performing substitution and/or deletion and/or addition of one or more amino acid residues on an amino acid sequence of the polypeptide defined by any of (a1) and (a2)and has the same function as the polypeptide defined by any of (a1) and (a2). The Chikungunya virus specific detection antigen has relatively high specificity and sensitivity in detection of Chikungunya virus serum infection.

The invention discloses an immunodiagnosis kit for specifically detecting a chikungunya virus NSP1 antigen. The diagnostic kit comprises a microporous reaction plate coated with a monoclonal antibodyCHIKV-M2, a sample treatment solution, a monoclonal antibody CHIKV-M10 combined with a marker, positive control, negative control, a concentrated washing solution, a developing solution and a stop solution. The kit can specifically detect the chikungunya virus antigen, has no cross reaction with other arbovirus antigens, and detects chikungunya virus culture supernatant sensitivity similar to thatof a commercial fluorescent quantitative PCR detection kit.

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.